Updates on psoriasis and cutaneous oncology proceedings from the 2013 mauiderm meeting

Journal of Clinical and Aesthetic Dermatology

Volumn 6, Issue 9 SUPPL., 2013, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; AMINOLEVULINIC ACID; APREMILAST; BRIAKINUMAB; BRODALUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; DICLOFENAC; EFALIZUMAB; EFFUDEX; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; FOSTAMATINIB; FP 187; FUMARIC ACID; GUSELKUMAB; IMIQUIMOD; INFLIXIMAB; INGENOL MEBUTATE; INTERLEUKIN 8; IXEKIZUMAB; METHOTREXATE; PLACEBO; PONESIMOD; SECUKINUMAB; TILDRAKIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VOCLOSPORIN;

ACTINIC KERATOSIS; ARTICLE; BASAL CELL CARCINOMA; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EPIDERMODYSPLASIA VERRUCIFORMIS; GENETIC SUSCEPTIBILITY; HUMAN; INNATE IMMUNITY; MORBIDITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIATIC ARTHRITIS; SKIN CANCER; SKIN CARCINOGENESIS; SKIN CARCINOMA; TUMOR VIRUS;

EID: 84897543761     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341-1348.
2. Capon F, Burden AD, Trembath RC, Barker JN. Psoriasis and other complex trait dermatoses: from Loci to functional pathways. J Invest Dermatol. 2012;132(3 Pt 2):915-922.
3. Ellinghaus D, Ellinghaus E, Nair RP, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90(4):636-647.
4. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New Engl J Med. 2011;365(7):620-628.
5. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. May 4 2012;90(5):784-795.
6. Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PloS one. 2011;6(2):e17160.
7. Gudjonsson JE, Krueger G. A role for epigenetics in psoriasis: methylated Cytosine-Guanine sites differentiate lesional from nonlesional skin and from normal skin. J Invest Dermatol. 2012;132(3 Pt 1):506-508.
8. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol (Baltimore). 2011;186(3):1495-1502.
9. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1): 145-154; e149.
10. Rich P, Sigurgeirsson B, Thaci DP, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomised, double-blind, placebo-controlled, phase II regimenfinding study. Br J Dermatol. 2012 Sep 29.
11. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412-421.
12. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New Engl J Med. 2012;366(13):1190-1199.
13. Wu JJ. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. New Engl J Med. 2012;367(3):274-275; author reply 275.
14. Reich K. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. New Engl J Med. 2012;367(3):274; author reply 275.
15. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an antiinterleukin-17- receptor antibody for psoriasis. New Engl J Med. 2012;366(13):1181-1189.
16. Yong PF, Freeman AF, Engelhardt KR, et al. An update on the hyper-IgE syndromes. Arthritis Res Ther. 2012;14(6):228.
17. Butcher M, Galkina E. Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost. 2011;106(5):787-795.
18. Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300-312.
19. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167(4):717-724.
20. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013 Jun 3.
21. Nickoloff B, Stevens S. What have we larned in dermatology from the biologic therapies? J Am Acad Dermatol. 2006;54(3Suppl):S143-S151.
22. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-1674.
23. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-1684.
24. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864-871.
25. Kimball AB, Papp KA, Wasfi Y, et al; on behalf of the PHOENIX 1
26. Papp K, Griffiths C, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844-854.
27. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011;165(5):1109-1117.
28. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. New Engl J Med. 2011;365(17):1586-1596.
29. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial. Lancet. 2012;380(9843):738-746.
30. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: A Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668-677.
31. O'Garra A, Stockinger B, Veldhoen M. Differentiation of human T(H)-17 cells does require TGF-beta! Nat Immunol. 2008;9(6):588-590.
32. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633- 640.
33. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebocontrolled PSUMMIT 1 trial. Lancet. 2013 Jun 12.
34. Ritchlin C, Gottliebe A, McInnes I, et al. Ustekinumab in active psoriatic athritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study. Washington, D.C.: American College of Rheumatology; November 9-14, 2012.
35. Cohen SA, Krishnaswami S, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: Analyses of efficacy and safety of 10 versus 5 mg twice daily in a pooled phase 3 and long-term extension rheumatoid arthritis population. Washington, D.C.: American College of Rheumatology; November 9-14, 2012.
36. Kavanaugh A, Mease P, Gomez-Reino J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled tiral. Arthritis Rheum. 2012;64(12):4168.
37. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8-entheseal resident T cells. Nat Med. 2012;18(7): 1069-1076.
38. Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev (Online). 2011(2):CD007649.
39. What are biosimilars and are they important? Drug Ther Bull. 2013;51(5):57-60.
40. Chamberlain P. Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations. Bioanalysis. 2013;5(5): 561-574.
41. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321-328.
42. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-534.
43. Mazlin MB, Chang CC, Baba R. Comorbidities associated with psoriasis -data from the malaysian psoriasis registry. Med J Malaysia. 2012;67(5):518-521.
44. Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes mellitus: A Danish nationwide cohort study. Diabetes Care. 2013 Mar 14.
45. Prey S, Paul C, Bronsard V, et al. Cardiovascular risk factors in patients with plaque psoriasis: A systematic review of epidemiological studies. J Eur Acad Dermatol Venereol. 2010;24(Suppl 2):23-30.
46. Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: A systematic review and meta-analysis. Br J Dermatol. 2013 Jun 18.
47. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14): 1735-1741.
48. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The "psoriatic march": A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4): 303-307.
49. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2): 262-267.
50. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(5):670-675.
51. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244-1250.
52. Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210-1217.
53. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Engl J Med. 2007;356(6):580-592.
54. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A metaanalysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622-627.
55. Hugh J, Van Voorhees AS, Nijhawan RI. The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. In press.
56. Ad Hoc Task F, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531-550.
57. Lang PG, Jr., Braun MA, Kwatra R. Aggressive squamous carcinomas of the scalp. Dermatol Surg. 2006;32(9): 1163-1170.
58. Brown MD, Zachary CB, Grekin RC, Swanson NA. Penile tumors: Their management by Mohs micrographic surgery. J Dermat Surg Oncol. 1987;13(11):1163-1167.
59. Brown MD, Zachary CB, Grekin RC, Swanson NA. Genital tumors: Their management by micrographic surgery. J Am Acad Dermatol. 1988;18(1 Pt 1):115-122.
60. DeAmbrosis K, De'Ambrosis B. Nonmelanoma skin cancer with perineural invasion: report of outcomes of a case series. Dermatol Surg. 2010;36(1):133-138.
61. Ross AS, Whalen FM, Elenitsas R, et al. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: An investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35(12): 1859-1866.
62. Miller SJ, Alam M, Andersen J, et al. Basal cell and squamous cell skin cancers. J Natl Compr Canc Netw. 2007;5(5): 506-529.
63. Leibovitch I, Huilgol SC, Selva D, et al. Basosquamous carcinoma: Treatment with Mohs micrographic surgery. Cancer. 2005;104(1):170-175.
64. Nindl I, Stockfleth E, Hofmann TG. Report on the 6th International Conference of HPV, Polyomavirus, and UV Radiation in Skin Cancer. J Invest Dermatol. 2013;133(7): 1702-1705.
65. Lebwohl MG, Rosen T, Stockfleth E. The role of human papillomavirus in common skin conditions: current viewpoints and therapeutic options. Cutis. 2010;86(5 Suppl):1-11; quiz suppl 12.
66. Muschik D, Braspenning-Wesch I, Stockfleth E, et al. Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PloS one. 2011;6(11):e27655.
67. Antonsson A, Waterboer T, Bouwes Bavinck JN, et al. Longitudinal study of seroprevalence and serostability of 34 human papillomavirus types in European organ transplant recipients. Virology. 2013;436(1):91-99.
68. de Vries E, Trakatelli M, Kalabalikis D, et al. Known and potential new risk factors for skin cancer in European populations: A multicentre case-control study. Br J Dermatol. 2012;167(Suppl 2):1-13.
69. Stockfleth E, Hinrichs B, Surber C, Christophers E. Prevention initiative for dermatological malignancies: where do we stand? Br J Dermatol. 2012;167(Suppl 2):v-vi.
70. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990-1000.
71. Jorizzo J, Stewart D, Bucko A, et al. Randomized trial evaluating a new 0.5% fluorouracil formulation demonstrates efficacy after 1-, 2-, or 4-week treatment in patients with actinic keratosis. Cutis. 2002;70(6):335-339.
72. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22-29.
73. Zeichner JA, Stern DW, Uliasz A, et al. Placebo-controlled, doubleblind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol. 2009;60(1):59-62.
74. Gupta AK, Paquet M. Ingenol mebutate: A promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17(3):173-179.
75. Lebwohl M, Shumack S, Stein Gold L, et al. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatology (Chicago, IL). 2013;149(6): 666-670.